A Phase 1b, Single Center, Clinical Study to Investigate the Safety and Biological Responses to Baminercept in Patients With Chronic HCV Hepatitis.

Chronic HCV Hepatitis C Clinical Trial

Status Not yet recruiting

Clinical Trial Summary

Erstes Safety Trial mit Baminercept in chronischen HCV Patienten. Untersuchung des potentiell antiviralen, antiinflammatorischen Effekts sowie Modulation der hepatischen Gen-Expression.

10 Patienten, open label, 10 Wochen Therapie. Sequentielles Enrollement der ersten 4 Patienten.

• Trial with medicinal product

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Chronic HCV Hepatitis C
• Hepatitis

• NCT number: NCT01164384
• Study type: Interventional
• Source: University of Zurich
• Contact: 01 Studienregister MasterAdmins
• Phone: +41 (0)44 255 11 11
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: October 2010
• Completion date: February 2013